Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Optimizing surgical decisions in young adults with breast cancer

Clinical Trial Details

The purpose of this study is to help us learn how best to support young women making decisions about breast cancer surgery.

Over the course of this study, a web-based decision support tool (“CONSYDER”) designed for women between the ages of 18-44 who are newly diagnosed with breast cancer and making decisions about breast cancer surgery, will begin to be offered as standard of care at each study site. Because sites will be provided access to CONSYDER at different times, some study participants will have access to the tool while others will not.

All participants (whether their site has begun offering CONSYDER or not) will be asked to complete surveys (at enrollment and about 6 months after surgery) that include questions about decision-making, breast cancer knowledge, treatment goals and preferences, anxiety, communication, as well as socio-demographic/background information.

Participants who receive neoadjuvant chemotherapy, will also be surveyed following completion of neoadjuvant treatment prior to their scheduled surgery. For participants who enroll when CONSYDER is available at their site, we will evaluate the implementation of CONSYDER as well as the experience of using the tool from the participant perspective.

Before surgery, we will ask a small number of participants and their surgeons to agree to have their pre-surgery consultation with their surgeons audio recorded. This will allow us to better understand how discussions between young women and their surgeons might influence surgical choice and identify opportunities to improve this process.

After surgery, some participants may be offered the opportunity for a one-on-one interview.

Key Eligibility: 

Inclusion Criteria: 
   1. Female aged 18-44 
   2. New diagnosis of stage 0, 1, 2 or 3 unilateral breast cancer 
   3. English or Spanish speaking 
   
Exclusion criteria: 
   1. Diagnosis of de no stage 4 breast cancer 
   2. Recurrent early-stage breast cancer 
   3. Bilateral breast cancer

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2308026433

Status

Not Yet Recruiting

Age Group

Adult

Sponsor

Disease